CAR-T Cell Therapy Market size was valued at USD 3.52 Bn. in 2023 and the total revenue is expected to grow at a CAGR of 34 % through 2024 to 2030, reaching nearly USD 27.31 Bn.Global CAR-T Cell Therapy Market Overview:
Chimeric antigen receptor (CAR) T-cell therapy is a way to get immune cells called T cells (a type of white blood cell) to fight cancer by changing them in the lab so they can find and destroy cancer cells. CAR T-cell therapy is a type of cell-based gene therapy it involves altering the genes inside T cells to help them attack cancer.Global CAR-T Cell Therapy Market Dynamics:
Rising prevalence of cancer coupled with high demand for effective treatment to cure cancer is driving the market growth. Recent studies suggest that over 1.7 million new cancer patients are recorded in U.S. alone and nearly 4.3 million in China. A rising number of adults and children developing cancer is expected to increase demand for effective and reliable therapeutic treatment approach for the improvement of the quality of patient’s lives. Moreover, the development of new and effective therapy options to cure symptoms of the disease is also contributing to the growth of the CAR-T cell therapy market. Increasing government initiatives for improving health care infrastructure and promoting research for cell therapy in cancer is fueling the growth of the market. In December 2022, the National Cancer Advisory Board authorized US$ 1.8 Bn in funding for Cancer Moonshot, which is an initiative taken up to accelerate research with an aim to make more therapies available to patients with cancer. However, High costs associated with CAR-T therapy and lack of cost-effective therapies for cancer have influenced the health conditions of the population and have led to a low average life expectancy. These factors may hinder the market growth. The report has profiled eighteen key players in the market from different regions. However, report has considered all market leaders, followers and new entrants with investors while analyzing the market and estimation the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the cost, availability of advanced technology is analyzed and report has come up with recommendations for future hot spot in APAC region.To know about the Research Methodology :- Request Free Sample Report
Global CAR-T Cell Therapy Market Segment Analysis:
The global CAR-T Cell Therapy market is segmented on the basis of Target Antigen, Therapeutic Application and End-Users. Based on Target Antigen, CD19/CD22 target antigens are estimated to hold the largest market share. The strong growth is creditable to the high approval rate of the antigens and their commercialization. On the other hand, BCMA (B-cell maturation antigen) segment is anticipated to record a robust growth rate growth over the forecasted years. Based on Therapeutic Application, diffuse large B-cell lymphoma is expected to dominate the global market. It accounted for xx% of the total market share in 2023. The Multiple Myeloma (MM) segment is expected to register a significant growth rate over the forecast period.CAR-T Cell Therapy Market Regional Insights:
North America dominated the largest CAR-T Cell Therapy Market share in 2023. North America’s market growth is attributed due to the rapid development and launch of new therapies for the treatment of cancer by key players in the market. For instance, in August 2022, the U.S. Food and Drug Administration (FDA) approved Kymriah, a CAR-T cell therapy to treat pediatric and young adult patients suffering from a form of acute lymphoblastic leukemia. Moreover, a large patient pool suffering from cancer in the U.S. and Canada is expected to further fuel the growth of the region in the global market. For instance, according to the Centers for Disease Control and Prevention (CDC) 2021, around 171,000 patients with blood cancer are diagnosed each year in the U.S. Europe is expected to hold the second-largest market during the forecast period. Asia Pacific is expected to witness lucrative growth during forecast period. Asia Pacific is expected to exhibit the highest growth over the forecast period, owing to the increasing number of global players collaborating and signing research as well as manufacturing contracts for CAR-T cell therapies with local players in the region. For instance, Cesca Therapeutics signed a license agreement with China-based, Boyalife Group, in March 2022, for CAR-T cell-related bioprocessing, development, and manufacturing outsourcing. The report also helps in understanding Global CAR-T Cell Therapy Market dynamics, structure by analyzing the market segments and project the Global CAR-T Cell Therapy Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global CAR-T Cell Therapy Market make the report investor’s guide.Global CAR-T Cell Therapy Market, Key developments:
In February 2022, the U.S. FDA granted approval of Breyanzi (lisocabtagene maraleucel) to Juno Therapeutics, a Bristol-Myers Squibb company. Breyanzi is approved for the treatment of adults with relapsed or refractory large-B-cell lymphoma who have not responded to, or who have relapsed after, at least two other types of systemic treatment. In July 2020, the U.S. FDA approved the third CAR-T cell therapy, approving Kite Pharma’s brexucabtagene autoleucel, sold as Tecartus. It is the first CAR-T therapeutic to treat relapsed or refractory mantle cell lymphoma (MCL). The approval of these early CAR-T cell therapies has opened the gates for many other types of cell and gene therapies to claim respect, from regulators, as well as the scientific and medical community at large.CAR-T Cell Therapy Market Ecosystem
Global CAR-T Cell Therapy Market Scope: Inquire before buying
Global CAR-T Cell Therapy Market Report Coverage Details Base Year: 2023 Forecast Period: 2024-2030 Historical Data: 2018 to 2023 Market Size in 2023: USD 3.52 Bn Forecast Period 2024 to 2030 CAGR: 34% Market Size in 2030: USD 27.31 Bn Segments Covered: by Target Antigen CD 19/ CD 22 HER 1 BCMA Others by Therapeutic Application Acute Lymphocytic Leukemia Diffuse large B-cell lymphoma Chronic Lymphocytic Leukemia Hepatocellular Carcinoma Others by End-Users Hospitals Cancer Research Institutes Clinics & Ambulatory Centers Global CAR-T Cell Therapy Market, by Region:
North America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria, Turkey, Russia and Rest of Europe) Asia Pacific (China, India, Japan, South Korea, Australia, ASEAN and Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina, Columbia and Rest of South America)Global CAR-T Cell Therapy Market, Key Players are
1. Gilead Sciences 2. Novartis AG 3. Gracell Biotechnology Ltd 4. Aeon Therapeutics 5. CARsgen Therapeutics 6. Daiichi Sankyo 7. Celegne 8. Otsuka Pharmaceutical 9. Biocon 10. Ono Pharmaceutical 11. Japan Tissue Engineering 12. Nipro Corporation 13. Takeda Pharmaceutical Company 14. Astellas Pharma 15. PersonGen Biomedicine 16. Hebei Senlang Biotech 17. Eli Lilly and Company 18. Johnson & Johnson Private LimitedFrequently Asked Questions:
1] Which region has the largest share in Global CAR-T Cell Therapy Market? Ans. North America region held the highest share in 2023. 2] What is the growth rate of Global CAR-T Cell Therapy Market? Ans. The Global CAR-T Cell Therapy Market is growing at a CAGR of 34% during forecasting period 2024-2030. 3] What is scope of the Global market report? Ans. Global market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period. 4] Who are the key players in Global market? Ans. The important key players in the Global market are – Gilead Sciences, Novartis AG, Gracell Biotechnology Ltd, Aeon Therapeutics, CARsgen Therapeutics, Daiichi Sankyo, Celegne, Otsuka Pharmaceutical, Biocon, Ono Pharmaceutical, Japan Tissue Engineering, Nipro Corporation, Takeda Pharmaceutical Company, Astellas Pharma, PersonGen Biomedicine, Hebei Senlang Biotech, Eli Lilly and Company, and Johnson & Johnson Private Limited 5] What is the study period of this market? Ans. The Global market is studied from 2018 to 2030.
1. CAR-T Cell Therapy Market Introduction 1.1. Study Assumption and Market Definition 1.2. Scope of the Study 1.3. Executive Summary 2. Global CAR-T Cell Therapy Market: Competitive Landscape 2.1. MMR Competition Matrix 2.2. Competitive Landscape 2.3. Market share analysis of major players 2.4. Key Players Benchmarking 2.4.1. Company Name 2.4.2. Target Antigen Segment 2.4.3. End-user Segment 2.4.4. Revenue (2023) 2.4.5. Key Development 2.4.6. Geographic distribution of major customers 2.5. Market Structure 2.5.1. Market Leaders 2.5.2. Market Followers 2.5.3. Emerging Players 2.6. Mergers and Acquisitions Details 3. CAR-T Cell Therapy Market: Dynamics 3.1. CAR-T Cell Therapy Market Trends 3.2. CAR-T Cell Therapy Market Dynamics 3.2.1. Drivers 3.2.2. Restraints 3.2.3. Opportunities 3.2.4. Challenges 3.3. Trends/disruptions impacting customer business 3.4. Ecosystem Analysis 3.4.1. Top Companies in the Industry Ecosystem Analysis 3.4.2. Role of key players in Ecosystem 3.5. Technology Analysis 3.5.1. Key technologies 3.5.1.1. Cell culture and expansion techniques 3.5.2. Complimentary technologies 3.5.2.1. Gene editing technology 3.5.3. Adjacent technologies 3.5.3.1. Monitoring and imaging technologies 3.6. Investment and funding scenario 3.7. PORTER’s Five Forces Analysis 3.7.1. Intensity of the Rivalry 3.7.2. Threat of New Entrants 3.7.3. Bargaining Power of Suppliers 3.7.4. Bargaining Power of Buyers 3.7.5. Threat of Substitutes 3.8. Regulatory Landscape by Region 3.8.1. North America 3.8.2. Europe 3.8.3. Asia Pacific 3.8.4. South America 3.8.5. MEA 4. CAR-T Cell Therapy Market: Global Market Size and Forecast by Segmentation (by Value in USD Mn) (2023-2030) 4.1. CAR-T Cell Therapy Market Size and Forecast, by Target Antigen (2023-2030) 4.1.1. CD 19/ CD 22 4.1.2. HER 1 4.1.3. BCMA 4.1.4. Others 4.2. CAR-T Cell Therapy Market Size and Forecast, by Therapeutic Application (2023-2030) 4.2.1. Acute Lymphocytic Leukemia 4.2.2. Diffuse large B-cell lymphoma 4.2.3. Chronic Lymphocytic Leukemia 4.2.4. Hepatocellular Carcinoma 4.2.5. Others 4.3. CAR-T Cell Therapy Market Size and Forecast, by End-Users (2023-2030) 4.3.1. Hospitals 4.3.2. Cancer Research Institutes 4.3.3. Clinics & Ambulatory Centers 5. North America CAR-T Cell Therapy Market Size and Forecast by Segmentation (by Value in USD Million) (2023-2030) 5.1. North America CAR-T Cell Therapy Market Size and Forecast, by Target Antigen (2023-2030) 5.1.1. CD 19/ CD 22 5.1.2. HER 1 5.1.3. BCMA 5.1.4. Others 5.2. North America CAR-T Cell Therapy Market Size and Forecast, by Therapeutic Application (2023-2030) 5.2.1. Acute Lymphocytic Leukemia 5.2.2. Diffuse large B-cell lymphoma 5.2.3. Chronic Lymphocytic Leukemia 5.2.4. Hepatocellular Carcinoma 5.2.5. Others 5.3. North America CAR-T Cell Therapy Market Size and Forecast, by End-Users (2023-2030) 5.3.1. Hospitals 5.3.2. Cancer Research Institutes 5.3.3. Clinics & Ambulatory Centers 5.4. North America CAR-T Cell Therapy Market Size and Forecast, by Country (2023-2030) 5.4.1. United States 5.4.1.1. United States CAR-T Cell Therapy Market Size and Forecast, by Target Antigen (2023-2030) 5.4.1.1.1. CD 19/ CD 22 5.4.1.1.2. HER 1 5.4.1.1.3. BCMA 5.4.1.1.4. Others 5.4.1.2. United States CAR-T Cell Therapy Market Size and Forecast, by Therapeutic Application (2023-2030) 5.4.1.2.1. Acute Lymphocytic Leukemia 5.4.1.2.2. Diffuse large B-cell lymphoma 5.4.1.2.3. Chronic Lymphocytic Leukemia 5.4.1.2.4. Hepatocellular Carcinoma 5.4.1.2.5. Others 5.4.1.3. United States CAR-T Cell Therapy Market Size and Forecast, by End-Users (2023-2030) 5.4.1.3.1. Hospitals 5.4.1.3.2. Cancer Research Institutes 5.4.1.3.3. Clinics & Ambulatory Centers 5.4.2. Canada 5.4.2.1. Canada CAR-T Cell Therapy Market Size and Forecast, by Target Antigen (2023-2030) 5.4.2.1.1. CD 19/ CD 22 5.4.2.1.2. HER 1 5.4.2.1.3. BCMA 5.4.2.1.4. Others 5.4.2.2. Canada CAR-T Cell Therapy Market Size and Forecast, by Therapeutic Application (2023-2030) 5.4.2.2.1. Acute Lymphocytic Leukemia 5.4.2.2.2. Diffuse large B-cell lymphoma 5.4.2.2.3. Chronic Lymphocytic Leukemia 5.4.2.2.4. Hepatocellular Carcinoma 5.4.2.2.5. Others 5.4.2.3. Canada CAR-T Cell Therapy Market Size and Forecast, by End-Users (2023-2030) 5.4.2.3.1. Hospitals 5.4.2.3.2. Cancer Research Institutes 5.4.2.3.3. Clinics & Ambulatory Centers 5.4.3. Mexico 5.4.3.1. Mexico CAR-T Cell Therapy Market Size and Forecast, by Target Antigen (2023-2030) 5.4.3.1.1. CD 19/ CD 22 5.4.3.1.2. HER 1 5.4.3.1.3. BCMA 5.4.3.1.4. Others 5.4.3.2. Mexico CAR-T Cell Therapy Market Size and Forecast, by Therapeutic Application (2023-2030) 5.4.3.2.1. Acute Lymphocytic Leukemia 5.4.3.2.2. Diffuse large B-cell lymphoma 5.4.3.2.3. Chronic Lymphocytic Leukemia 5.4.3.2.4. Hepatocellular Carcinoma 5.4.3.2.5. Others 5.4.3.3. Mexico CAR-T Cell Therapy Market Size and Forecast, by End-Users (2023-2030) 5.4.3.3.1. Hospitals 5.4.3.3.2. Cancer Research Institutes 5.4.3.3.3. Clinics & Ambulatory Centers 6. Europe CAR-T Cell Therapy Market Size and Forecast by Segmentation (by Value in USD Million) (2023-2030) 6.1. Europe CAR-T Cell Therapy Market Size and Forecast, by Target Antigen (2023-2030) 6.2. Europe CAR-T Cell Therapy Market Size and Forecast, by Therapeutic Application (2023-2030) 6.3. Europe CAR-T Cell Therapy Market Size and Forecast, by End-Users (2023-2030) 6.4. Europe CAR-T Cell Therapy Market Size and Forecast, by Country (2023-2030) 6.4.1. United Kingdom 6.4.1.1. United Kingdom CAR-T Cell Therapy Market Size and Forecast, by Target Antigen (2023-2030) 6.4.1.2. United Kingdom CAR-T Cell Therapy Market Size and Forecast, by Therapeutic Application (2023-2030) 6.4.1.3. United Kingdom CAR-T Cell Therapy Market Size and Forecast, by End-Users (2023-2030) 6.4.2. France 6.4.2.1. France CAR-T Cell Therapy Market Size and Forecast, by Target Antigen (2023-2030) 6.4.2.2. France CAR-T Cell Therapy Market Size and Forecast, by Therapeutic Application (2023-2030) 6.4.2.3. France CAR-T Cell Therapy Market Size and Forecast, by End-Users (2023-2030) 6.4.3. Germany 6.4.3.1. Germany CAR-T Cell Therapy Market Size and Forecast, by Target Antigen (2023-2030) 6.4.3.2. Germany CAR-T Cell Therapy Market Size and Forecast, by Therapeutic Application (2023-2030) 6.4.3.3. Germany CAR-T Cell Therapy Market Size and Forecast, by End-Users (2023-2030) 6.4.4. Italy 6.4.4.1. Italy CAR-T Cell Therapy Market Size and Forecast, by Target Antigen (2023-2030) 6.4.4.2. Italy CAR-T Cell Therapy Market Size and Forecast, by Therapeutic Application (2023-2030) 6.4.4.3. Italy CAR-T Cell Therapy Market Size and Forecast, by End-Users (2023-2030) 6.4.5. Spain 6.4.5.1. Spain CAR-T Cell Therapy Market Size and Forecast, by Target Antigen (2023-2030) 6.4.5.2. Spain CAR-T Cell Therapy Market Size and Forecast, by Therapeutic Application (2023-2030) 6.4.5.3. Spain CAR-T Cell Therapy Market Size and Forecast, by End-Users (2023-2030) 6.4.6. Sweden 6.4.6.1. Sweden CAR-T Cell Therapy Market Size and Forecast, by Target Antigen (2023-2030) 6.4.6.2. Sweden CAR-T Cell Therapy Market Size and Forecast, by Therapeutic Application (2023-2030) 6.4.6.3. Sweden CAR-T Cell Therapy Market Size and Forecast, by End-Users (2023-2030) 6.4.7. Austria 6.4.7.1. Austria CAR-T Cell Therapy Market Size and Forecast, by Target Antigen (2023-2030) 6.4.7.2. Austria CAR-T Cell Therapy Market Size and Forecast, by Therapeutic Application (2023-2030) 6.4.7.3. Austria CAR-T Cell Therapy Market Size and Forecast, by End-Users (2023-2030) 6.4.8. Rest of Europe 6.4.8.1. Rest of Europe CAR-T Cell Therapy Market Size and Forecast, by Target Antigen (2023-2030) 6.4.8.2. Rest of Europe CAR-T Cell Therapy Market Size and Forecast, by Therapeutic Application (2023-2030) 6.4.8.3. Rest of Europe CAR-T Cell Therapy Market Size and Forecast, by End-Users (2023-2030) 7. Asia Pacific CAR-T Cell Therapy Market Size and Forecast by Segmentation (by Value in USD Million) (2023-2030) 7.1. Asia Pacific CAR-T Cell Therapy Market Size and Forecast, by Target Antigen (2023-2030) 7.2. Asia Pacific CAR-T Cell Therapy Market Size and Forecast, by Therapeutic Application (2023-2030) 7.3. Asia Pacific CAR-T Cell Therapy Market Size and Forecast, by End-Users (2023-2030) 7.4. Asia Pacific CAR-T Cell Therapy Market Size and Forecast, by Country (2023-2030) 7.4.1. China 7.4.1.1. China CAR-T Cell Therapy Market Size and Forecast, by Target Antigen (2023-2030) 7.4.1.2. China CAR-T Cell Therapy Market Size and Forecast, by Therapeutic Application (2023-2030) 7.4.1.3. China CAR-T Cell Therapy Market Size and Forecast, by End-Users (2023-2030) 7.4.2. S Korea 7.4.2.1. S Korea CAR-T Cell Therapy Market Size and Forecast, by Target Antigen (2023-2030) 7.4.2.2. S Korea CAR-T Cell Therapy Market Size and Forecast, by Therapeutic Application (2023-2030) 7.4.2.3. S Korea CAR-T Cell Therapy Market Size and Forecast, by End-Users (2023-2030) 7.4.3. Japan 7.4.3.1. Japan CAR-T Cell Therapy Market Size and Forecast, by Target Antigen (2023-2030) 7.4.3.2. Japan CAR-T Cell Therapy Market Size and Forecast, by Therapeutic Application (2023-2030) 7.4.3.3. Japan CAR-T Cell Therapy Market Size and Forecast, by End-Users (2023-2030) 7.4.4. India 7.4.4.1. India CAR-T Cell Therapy Market Size and Forecast, by Target Antigen (2023-2030) 7.4.4.2. India CAR-T Cell Therapy Market Size and Forecast, by Therapeutic Application (2023-2030) 7.4.4.3. India CAR-T Cell Therapy Market Size and Forecast, by End-Users (2023-2030) 7.4.5. Australia 7.4.5.1. Australia CAR-T Cell Therapy Market Size and Forecast, by Target Antigen (2023-2030) 7.4.5.2. Australia CAR-T Cell Therapy Market Size and Forecast, by Therapeutic Application (2023-2030) 7.4.5.3. Australia CAR-T Cell Therapy Market Size and Forecast, by End-Users (2023-2030) 7.4.6. ASIAN 7.4.6.1. ASIAN CAR-T Cell Therapy Market Size and Forecast, by Target Antigen (2023-2030) 7.4.6.2. ASIAN CAR-T Cell Therapy Market Size and Forecast, by Therapeutic Application (2023-2030) 7.4.6.3. ASIAN CAR-T Cell Therapy Market Size and Forecast, by End-Users (2023-2030) 7.4.7. Rest of Asia Pacific 7.4.7.1. Rest of Asia Pacific CAR-T Cell Therapy Market Size and Forecast, by Target Antigen (2023-2030) 7.4.7.2. Rest of Asia Pacific CAR-T Cell Therapy Market Size and Forecast, by Therapeutic Application (2023-2030) 7.4.7.3. Rest of Asia Pacific CAR-T Cell Therapy Market Size and Forecast, by End-Users (2023-2030) 8. Middle East and Africa CAR-T Cell Therapy Market Size and Forecast by Segmentation (by Value in USD Million) (2023-2030) 8.1. Middle East and Africa CAR-T Cell Therapy Market Size and Forecast, by Target Antigen (2023-2030) 8.2. Middle East and Africa CAR-T Cell Therapy Market Size and Forecast, by Therapeutic Application (2023-2030) 8.3. Middle East and Africa CAR-T Cell Therapy Market Size and Forecast, by End-Users (2023-2030) 8.4. Middle East and Africa CAR-T Cell Therapy Market Size and Forecast, by Country (2023-2030) 8.4.1. South Africa 8.4.1.1. South Africa CAR-T Cell Therapy Market Size and Forecast, by Target Antigen (2023-2030) 8.4.1.2. South Africa CAR-T Cell Therapy Market Size and Forecast, by Therapeutic Application (2023-2030) 8.4.1.3. South Africa CAR-T Cell Therapy Market Size and Forecast, by End-Users (2023-2030) 8.4.2. S GCC 8.4.2.1. GCC CAR-T Cell Therapy Market Size and Forecast, by Target Antigen (2023-2030) 8.4.2.2. GCC CAR-T Cell Therapy Market Size and Forecast, by Therapeutic Application (2023-2030) 8.4.2.3. GCC CAR-T Cell Therapy Market Size and Forecast, by End-Users (2023-2030) 8.4.3. Egypt 8.4.3.1. Egypt CAR-T Cell Therapy Market Size and Forecast, by Target Antigen (2023-2030) 8.4.3.2. Egypt CAR-T Cell Therapy Market Size and Forecast, by Therapeutic Application (2023-2030) 8.4.3.3. Egypt CAR-T Cell Therapy Market Size and Forecast, by End-Users (2023-2030) 8.4.4. Nigeria 8.4.4.1. Nigeria CAR-T Cell Therapy Market Size and Forecast, by Target Antigen (2023-2030) 8.4.4.2. Nigeria CAR-T Cell Therapy Market Size and Forecast, by Therapeutic Application (2023-2030) 8.4.4.3. Nigeria CAR-T Cell Therapy Market Size and Forecast, by End-Users (2023-2030) 8.4.5. Rest of ME &A 8.4.5.1. Rest of ME &A CAR-T Cell Therapy Market Size and Forecast, by Target Antigen (2023-2030) 8.4.5.2. Rest of ME &A CAR-T Cell Therapy Market Size and Forecast, by Therapeutic Application (2023-2030) 8.4.5.3. Rest of ME &A CAR-T Cell Therapy Market Size and Forecast, by End-Users (2023-2030) 9. South America CAR-T Cell Therapy Market Size and Forecast by Segmentation (by Value in USD Million) (2023-2030) 9.1. South America CAR-T Cell Therapy Market Size and Forecast, by Target Antigen (2023-2030) 9.2. South America CAR-T Cell Therapy Market Size and Forecast, by Therapeutic Application (2023-2030) 9.3. South America CAR-T Cell Therapy Market Size and Forecast, by End-Users (2023-2030) 9.4. South America CAR-T Cell Therapy Market Size and Forecast, by Country (2023-2030) 9.4.1. Brazil 9.4.1.1. Brazil CAR-T Cell Therapy Market Size and Forecast, by Target Antigen (2023-2030) 9.4.1.2. Brazil CAR-T Cell Therapy Market Size and Forecast, by Therapeutic Application (2023-2030) 9.4.1.3. Brazil CAR-T Cell Therapy Market Size and Forecast, by End-Users (2023-2030) 9.4.2. Argentina 9.4.2.1. Argentina CAR-T Cell Therapy Market Size and Forecast, by Target Antigen (2023-2030) 9.4.2.2. Argentina CAR-T Cell Therapy Market Size and Forecast, by Therapeutic Application (2023-2030) 9.4.2.3. Argentina CAR-T Cell Therapy Market Size and Forecast, by End-Users (2023-2030) 9.4.3. Rest Of South America 9.4.3.1. Rest of South America CAR-T Cell Therapy Market Size and Forecast, by Target Antigen (2023-2030) 9.4.3.2. Rest of South America CAR-T Cell Therapy Market Size and Forecast, by Therapeutic Application (2023-2030) 9.4.3.3. Rest of South America CAR-T Cell Therapy Market Size and Forecast, by End-Users (2023-2030) 10. Company Profile: Key Players 10.1. Gilead Sciences 10.1.1. Company Overview 10.1.2. Business Portfolio 10.1.3. Financial Overview 10.1.3.1. Total Revenue 10.1.3.2. Segment Revenue 10.1.3.3. Annual Revenue 10.1.4. SWOT Analysis 10.1.5. Strategic Analysis 10.1.6. Recent Developments 10.2. Novartis AG 10.3. Gracell Biotechnology Ltd 10.4. Aeon Therapeutics 10.5. CARsgen Therapeutics 10.6. Daiichi Sankyo 10.7. Celegne 10.8. Otsuka Pharmaceutical 10.9. Biocon 10.10. Ono Pharmaceutical 10.11. Japan Tissue Engineering 10.12. Nipro Corporation 10.13. Takeda Pharmaceutical Company 10.14. Astellas Pharma 10.15. PersonGen Biomedicine 10.16. Hebei Senlang Biotech 10.17. Eli Lilly and Company 10.18. Johnson & Johnson Private Limited 11. Key Findings and Analyst Recommendations 12. CAR-T Cell Therapy Market: Research Methodology 12.1. Research Data 12.2. Market breakdown and data triangulation 12.2.1. Secondary Data 12.2.1.1. Key data from secondary sources 12.2.2. Primary Data 12.2.2.1. Key data from Primary sources 12.2.2.2. Breakdown of primaries 12.3. Scope 12.4. Market size estimation 12.4.1.1. Bottom-up approach 12.4.1.2. Top-down approach 12.4.2. Demand side analysis 12.4.2.1. Regional analysis 12.4.2.2. Country level analysis 12.4.2.3. Assumptions for demand side analysis 12.4.2.4. Calculations for demand side analysis 12.4.3. Supply side analysis 12.4.3.1. Calculations for supply side analysis 12.4.3.2. Assumptions for supply side analysis
